Group health insurance costs are climbing steadily in 2025, with prescription drug claims driving a significant increase. Among these medications, GLP-1 receptor agonists, such as Ozempic, Wegovy, and Mounjaro, are at the center of discussion for both employees seeking coverage and employers balancing cost management.
According to the International Foundation of Employee Benefit Plans (IFEBP), GLP-1 drugs now account for over 10% of annual claims costs in U.S. health plans. As we move through the second half of 2025, employers are under increasing pressure to balance clinical demand, workforce wellness, and financial sustainability.
How GLP-1 Medications Work
Understanding GLP-1s for Diabetes and Weight Loss
GLP-1 receptor agonists mimic a natural hormone that helps regulate blood sugar, appetite, and digestion, making them highly effective for managing type 2 diabetes and supporting clinically meaningful weight loss.
By slowing the rate at which the stomach empties and signaling feelings of fullness, these medications reduce calorie intake while improving insulin sensitivity. This dual action not only lowers A1C levels in patients with diabetes but also leads to sustained weight reduction, which is why they are increasingly prescribed for a multitude of conditions.
From a pharmacy perspective, GLP-1s require long-term adherence to remain effective, and stopping treatment often leads to weight regain. Clinical research also suggests these drugs may reduce the risk of cardiovascular disease, kidney disease, and obesity-related complications, positioning them as one of the most influential and costly drug classes affecting Group Benefits programs today.
The Cost of GLP-1s in Group Health Insurance
Financial Impact on Employer-Sponsored Health Plans
GLP-1s are among the most expensive drug classes on the market, averaging close to $1,000 per patient per month and ranking as one of the top drivers of pharmacy spending in employer health plans.
Employers consistently rank GLP-1 coverage among their top three long-term affordability concerns, reflecting the strain these medications place on group health budgets. For businesses, decisions about whether—and how—to cover GLP-1 prescriptions have become strategically important for health benefits strategies, carrying both significant financial consequences and direct implications for workforce health outcomes.
Employer Coverage Trends in 2025
Large Employers Expanding Access, Smaller Firms Hesitate
The IFEBP 2025 Pulse Survey shows that coverage of GLP-1 medications continues to vary widely across employer health plans. Nearly all organizations now provide access to GLP-1s for type 2 diabetes management, reflecting their established role in controlling blood sugar and reducing complications. However, coverage for weight loss remains limited, even as employee demand continues to grow.
Larger employers are leading the way in expanding access, while mid-sized and smaller companies remain cautious due to high monthly drug costs and uncertainty about long-term outcomes. This uneven approach to coverage often creates frustration among employees who clinically qualify for GLP-1 treatment but find that their employer-sponsored benefits do not include these medications. For organizations competing for talent, this gap in coverage may increasingly influence employee satisfaction and retention.
Employer Strategies for Sustainable GLP-1 Coverage
Balancing Employee Access and Cost Control
Employers are adopting a range of strategies to provide access to GLP-1 medications while keeping group health plans financially sustainable. Common approaches include:
● Prior authorization to confirm that prescriptions meet clinical criteria before coverage begins.
● Step therapy protocols that require employees to try lower-cost alternatives or lifestyle interventions before advancing to GLP-1 treatment.
● BMI thresholds and comorbidity requirements that limit coverage to employees with obesity or obesity-related health conditions.
● Integrated care programs that pair GLP-1 prescriptions with wellness initiatives, nutrition counseling, and behavioral health support for better long-term outcomes.
● Value-based contracts that tie pharmacy reimbursement to patient health outcomes instead of the number of prescriptions filled.
By combining these Group Benefits strategies, employers can control rising pharmacy costs, align benefits with evidence-based care, and still respond to growing employee demand for GLP-1 coverage.
Key GLP-1 Takeaways for Employers
Balancing Costs and Long-Term Workforce Health
GLP-1 medications continue to reshape the Group Benefits landscape in 2025. While they present a clear cost challenge for employer health plans, these drugs also offer the potential for meaningful improvements in workforce health. Employees using GLP-1s to manage obesity or type 2 diabetes may experience fewer comorbidities, reduced absenteeism, and lower long-term medical expenses. The key question for employers is whether today’s short-term investment in GLP-1 coverage will translate into measurable savings and healthier employees over time.
As an employer building an Employee Benefits strategy, here’s what you need to know:
● GLP-1s are here to stay: They now account for more than 10% of employer health plan claims, and this trend is expected to continue.
● Coverage remains uneven: Nearly all plans cover diabetes use, but fewer extend coverage for obesity treatment.
● Costs are substantial: Monthly prescription costs average around $1,000 per patient.
● Program design makes the difference: Employers can manage affordability by applying prior authorization, step therapy, and integrated care programs.
For expert guidance on structuring Group Benefits to address GLP-1 coverage, contact SandStone Insurance Partners at .
Legal Disclaimer: Coverage terms, conditions, and exclusions vary by policy and insurer. The above material is for general educational purposes only and is not a substitute for professional insurance advice. The recommendation(s), advice, and contents of this material do not address every possible legal obligation, hazard, code violation, loss potential, or exception to best practice. SandStone Insurance Partners makes no warranty or representation that following any recommendations herein will render premises, property, or operations safe or legally compliant. Nothing in this material should be construed as establishing or confirming insurance coverage with SandStone Insurance Partners.
